TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01068301
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
Study: NCT03886922
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
Study: NCT00832364
Drug: Acitretin (also called U0279)
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules containing 25 mg U0279 taken once a day.
Study: NCT03464383
Drug: Escitalopram 10mg
Normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
Study: NCT03798834
Drug: Fascia iliaca block (FIB)
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound-guided Fascia iliaca block
Study: NCT01283321
Drug: Human fibrinogen concentrate
Normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g IV once, within 30 minutes of ACT \< 155 seconds, post CPB, with evidence of significant microvascular bleeding
Study: NCT01570608
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection 3 monthly injections thereafter as needed
Study: NCT02671383
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
Study: NCT02671383
Drug: Lopinavir
Normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
Study: NCT01570608
Drug: Verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin photodynamic therapy standard fluence
Study: NCT02890238
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
Study: NCT02890238
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg tab from 7th-11th day of the same cycle orally 3times/day
Study: NCT03248648
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
Study: NCT03248648
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
Study: NCT00956696
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
Study: NCT04239170
Drug: Camrelizumab(SHR-1210)
Normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin
Study: NCT02123368
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intraarticular injection of Hyaluronic acid (Hyal One)
Study: NCT01119014
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pill, 2,5-20 mg/day, maximum 16 weeks
Study: NCT01119014
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pill, 50-600mg/day, maximum 16 weeks
Study: NCT01806740
Drug: Gadoterate meglumine
Normalized name: Gadoterate meglumine
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
Study: NCT00346255
Drug: BB-10901
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.
Study: NCT02392611
Drug: Alobresib
Normalized name: Alobresib
DrugBank: Alobresib (DB14970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle
Study: NCT02392611
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle
Study: NCT02392611
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days
Study: NCT02913716
Drug: defactinib
Normalized name: Defactinib
DrugBank: Defactinib (DB12282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 400 mg \[14C\]-defactinib
Study: NCT00193349
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00193349
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00193349
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006299
Drug: Celebrex
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02983799
Drug: OLAPARIB
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg olaparib tablets taken orally twice daily
Study: NCT01797315
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00845507
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
Study: NCT00543400
Drug: M118
Normalized name: Fondaparinux sodium
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous (IV) infusion
Study: NCT00543400
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT02948959
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study: NCT02948959
Drug: Asthma Controller Therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral
Study: NCT02948959
Drug: Asthma Reliever Therapies
Normalized name: Bioease Pain Relieving Cold Therapy
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled
Study: NCT05258123
Drug: Ginkgo Biloba Extract
Normalized name: Ginkgo biloba extract
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract with 360mg was administered
Study: NCT02342665
Drug: Copanlisib (BAY80-6946)
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
Study: NCT01545440
Drug: lebrikizumab
Normalized name: Lebrikizumab
DrugBank: Lebrikizumab (DB11914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous dose every 4 weeks
Study: NCT02239081
Drug: CTP-730
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT00101153
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00101153
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00223249
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01778946
Drug: Low Dose Nicotine (7mg)
Normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01778946
Drug: Moderate Dose Nicotine (14mg)
Normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03046511
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
Study: NCT00101153
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02618720
Drug: ornidazole
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01583738
Drug: V0251
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single dose
Study: NCT00993798
Drug: SABER-Bupivacaine Treatment 1a
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.0 ml
Study: NCT00993798
Drug: Placebo SABER-Bupivacaine Treatment 1b
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.0 ml
Study: NCT00993798
Drug: Bupivacaine HCl Treatment 1c
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20.0 ml
Study: NCT00993798
Drug: SABER-Bupivacaine Treatment 2a
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 ml
Study: NCT00993798
Drug: Placebo SABER-Bupivacaine Treatment 2b
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 ml
Study: NCT00993798
Drug: Bupivacaine HCl Treatment 2c
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20.0 ml
Study: NCT00335686
Drug: Nevirapine (Viramune): 1 comp (200mg)/12h
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (Viramune): 1 comp (200mg)/12h
Study: NCT02080195
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2/day on Days -6 through -2.
Study: NCT02080195
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting on Day 5. Dose will be adjusted according to blood levels.
Study: NCT02080195
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/kg three times per day from Day 5 to Day 35.
Study: NCT02080195
Drug: Rabbit antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.
Study: NCT02560935
Drug: Hydroxyurea (Moderate Dose)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
Study: NCT02560935
Drug: Hydroxyurea (Low Dose)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
Study: NCT00103337
Drug: cilengitide
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04183634
Drug: Rotigotine TTS (Test)
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.
Study: NCT04183634
Drug: Neupro (Reference)
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.
Study: NCT01513863
Drug: Metronidazole Topical Gel 1%
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
Study: NCT01513863
Drug: Metronidazole Topical Gel 1% (Metrogel)
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
Study: NCT02461875
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.
Study: NCT02461875
Drug: GnRH antagonist rescue & cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
Study: NCT00519896
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00509002
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg by mouth once a day, every day, at about same time in morning.
Study: NCT00927355
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
Study: NCT01990703
Drug: Levonorgestrel IUD
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timing of IUD insertion
Study: NCT03719053
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.
Study: NCT03066622
Drug: 5mg rapidly dissolving olanzapine
Normalized name: olanzapine 5 MG
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg rapidly dissolving olanzapine
Study: NCT03380793
Drug: morinidazole
Normalized name: Morinidazole
DrugBank: Morinidazole (DB15098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
Study: NCT00641719
Drug: Duloxetine hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine 40 mg QD, PO, 1 year
Study: NCT00641719
Drug: Duloxetine hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine 60 mg QD, PO, 1 year
Study: NCT00547287
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
Study: NCT00547287
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
Study: NCT01105780
Drug: JNJ-41443532
Normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg tablet once daily for 1 day
Study: NCT02228824
Drug: Very low nicotine content cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.07 mg nicotine delivery
Study: NCT02228824
Drug: Normal nicotine content cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.8 mg nicotine delivery
Study: NCT02462850
Drug: CL-108
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00553098
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT00553098
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00553098
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT00825097
Drug: Botulinum toxin injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin type A
Study: NCT02584478
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly single agent Paclitaxel will be administered on Day 1, 8, and 15 of each 21-day cycle. Suggested dose: 80 mg/m\^2 intravenously or local standard.~Paclitaxel may also be administered once weekly with a 1-week break every 3 weeks in lieu of every week
Study: NCT01802814
Drug: SR-A + Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00315666
Drug: memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01802814
Drug: SR-B + Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03541044
Drug: Nicotine Prototype Mini lozenge
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of a prototype nicotine 2mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Study: NCT00066378
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00066378
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03304873
Drug: Retapamulin
Normalized name: Retapamulin
DrugBank: Retapamulin (DB01256)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
Study: NCT02542410
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02542410
Drug: Norethindrone acetate
Normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02584478
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily Topotecan on Days 1-5 of each 21-day cycle Suggested dose: 1.25 mg/m2 intravenously or local standard OR Weekly Topotecan with a 1 week break every 3 weeks. Suggested dose: 4 mg/m2 intravenously or local standard
Study: NCT01782729
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
Study: NCT03847467
Drug: 2'-Fucosyllactose
Normalized name: 2'-Fucosyllactose
DrugBank: 2'-Fucosyllactose (DB16052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk oligosaccharide prebiotic dietary supplement
Study: NCT00810758
Drug: PF-04878691 3mg
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 3mg, twice weekly, 2 weeks
Study: NCT00810758
Drug: PF-04878691 6mg
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 6mg, twice weekly, 2 weeks
Study: NCT00810758
Drug: PF-04878691 9mg
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 9mg, twice weekly, 2 weeks
Study: NCT02378532
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level. Based on the results of the DSMB an additional leven of 300mg was added.